Get started
Klotho Neurosciences, Inc. Warrant 2024-21.06.29 on Klotho NeuroscienceKlotho Neurosciences, Inc. Warrant 2024-21.06.29 on Klotho NeuroscienceKlotho Neurosciences, Inc. Warrant 2024-21.06.29 on Klotho Neuroscience

Klotho Neurosciences, Inc. Warrant 2024-21.06.29 on Klotho Neuroscience

No trades
OverviewFinancialsNewsCommunitySeasonals

Chart


Full chart

Key stats


Market capitalization
‪17.66 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.3268 USD
Net income (FY)
‪−6.15 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪65.68 M‬
Beta (1Y)
0.85

About Klotho Neurosciences, Inc.


Sector
Commercial Services
Industry
Miscellaneous Commercial Services
CEO
Joseph Sinkule
Website
klothoneuro.com
Headquarters
Omaha
Founded
2004
Identifiers
3
ISIN US49876K1117
Klotho Neurosciences, Inc. engages in the provision of new therapies to treat neurodegenerative diseases. It offers cell and gene therapy. The company was founded by Joseph Sinkule on August 2, 2004 and is headquartered in Omaha, NE.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.